Molecular classification of estrogen receptor-positive/luminal breast cancers

Advances in Anatomic Pathology

Volumn 19, Issue 1, 2012, Pages 39-53

  Geyer, Felipe C ^a   Rodrigues, Daniel N ^b   Weigelt, Britta ^c   Reis Filho, Jorge S ^b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

breast cancer; comparative genomic hybridization; estrogen receptor; microarrays; PIK3CA; PTEN

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE DERIVATIVE; CHLORDANE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EVEROLIMUS; EXEMESTANE; HORMONE; KI 67 ANTIGEN; LAPATINIB; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; NAVELBINE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; SURVIVIN; TAMOXIFEN; TAXANE DERIVATIVE; TEMSIROLIMUS; TRANSCRIPTOME; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; BREAST METASTASIS; CANCER CELL CULTURE; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER PATIENT; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME 16Q; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CLINICAL DECISION MAKING; COMPARATIVE GENOMIC HYBRIDIZATION; COPY NUMBER VARIATION; DISTANT METASTASIS; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC GAIN; GENETIC PREDISPOSITION; GENOME; HUMAN; IMMUNOHISTOCHEMISTRY; LOSS OF FUNCTION MUTATION; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MICROARRAY ANALYSIS; MULTICENTER STUDY (TOPIC); MULTIGENE FAMILY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS; RECEPTORS, ESTROGEN;

EID: 83755174643     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0b013e31823fafa0     Document Type: Review

References (139)

1. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009;360:790-800.
2. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2010;220:263-280.
3. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol. 2010; 4:192-208.
4. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol. 2009;6:718-730.
5. Doane AS, Danso M, Lal P, et al. An estrogen receptornegative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene. 2006;25:3994-4008. (Pubitemid 43990755)
6. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005;24:4660-4671. (Pubitemid 41032603)
7. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.
8. Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750-2767.
9. Prat A, Parker JS, Karginova O, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.
10. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008; 14:5158-5165.
11. Loi S, Haibe-Kains B, Majjaj S, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA. 2010;107:10208-10213.
12. Lopez-Garcia MA, Geyer FC, Lacroix-Triki M, et al. Breast cancer precursors revisited: molecular features and progression pathways. Histopathology. 2010;57:171-192.
13. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008;10:R65.
14. Weigel MT, Dowsett M. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010;17:R245-R262.
15. Mook S, Schmidt MK, Rutgers EJ, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospitalbased retrospective cohort study. Lancet Oncol. 2009;10: 1070-1076.
16. Gruvberger S, Ringner M, Chen Y, et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 2001;61:5979-5984. (Pubitemid 32762524)
17. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-752.
18. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160-1167.
19. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98:10869-10874. (Pubitemid 32878711)
20. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100:8418-8423. (Pubitemid 36842560)
21. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003;100:10393-10398. (Pubitemid 37071889)
22. Herschkowitz JI, Simin K, Weigman VJ, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8:R76.
23. Colombo PE, Milanezi F, Weigelt B, et al. Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res. 2011;13:212.
24. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication and prediction. Lancet. 2011. (In press.
25. Reis-Filho JS, Weigelt B, Fumagalli D, et al. Molecular profiling: moving away from tumor philately. Sci Transl Med. 2010;2:47ps43.
26. Haibe-Kains B, Culhane A, Desmedt C, et al. Robustness of breast cancer molecular subtypes identification. Ann Oncol. 2010;21:iv49-iv59.
27. Weigelt B, Mackay A, A'Hern R, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010;11:339-349.
28. Weigelt B, Pusztai L, Ashworth A, et al. Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol. 2011. DOI: 10.1038/nrclinonc.2011.125. [Epub ahead of print].
29. Pusztai L, Mazouni C, Anderson K, et al. Molecular classification of breast cancer: limitations and potential. Oncologist. 2006;11:868-877. (Pubitemid 44373759)
30. Kapp AV, Tibshirani R. Are clusters found in one dataset present in another dataset? Biostatistics. 2007;8:9-31. (Pubitemid 44906101)
31. Mackay A, Weigelt B, Grigoriadis A, et al. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst. 2011;103:662-673.
32. Lusa L, McShane LM, Reid JF, et al. Challenges in projecting clustering results across gene expression-profiling datasets. J Natl Cancer Inst. 2007;99:1715-1723. (Pubitemid 351767219)
33. Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci USA. 2005;102:3738-3743. (Pubitemid 40354681)
34. Fan C, Oh DS, Wessels L, et al. Concordance among geneexpression- based predictors for breast cancer. N Engl J Med. 2006;355:560-569. (Pubitemid 44200649)
35. Reyal F, van Vliet MH, Armstrong NJ, et al. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res. 2008;10:R93.
36. Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptorpositive breast cancer. Clin Cancer Res. 2010;16:5222-5232.
37. Cleator SJ, Powles TJ, Dexter T, et al. The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res. 2006;8:R32.
38. Elloumi F, Hu Z, Li Y, et al. Systematic bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples. BMC Med Genomics. 2011;4:54.
39. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502. (Pubitemid 43854964)
40. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-750.
41. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736-1747.
42. Cheang MC, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008; 14:1368-1376. (Pubitemid 351413917)
43. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10: 5367-5374. (Pubitemid 39100473)
44. Dunbier AK, Anderson H, Ghazoui Z, et al. Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids. 2011;76:736-740.
45. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor- rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol. 2011; 29:2342-2349.
46. Iwamoto T, Lee JS, Bianchini G, et al. First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. Breast Cancer Res Treat. 2011; 130:155-164.
47. Penault-Llorca F, Andre F, Sagan C, et al. Ki67 expression and docetaxel efficacy in patients with estrogen receptorpositive breast cancer. J Clin Oncol. 2009;27:2809-2815.
48. Guedj M, Marisa L, de Reynies A, et al. A refined molecular taxonomy of breast cancer. Oncogene. 2011. Jul 25. Doi: 10.1038/onc.2011.301. [Epub ahead of print].
49. Peppercorn J, Perou CM, Carey LA. Molecular subtypes in breast cancer evaluation and management: divide and conquer. Cancer Invest. 2008;26:1-10.
50. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087-2106. (Pubitemid 41797643)
51. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415:530-536. (Pubitemid 34130608)
52. van de Vijver MJ, He YD, van't Veer LJ, et al. A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009. (Pubitemid 35461656)
53. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet. 2005;365:671-679. (Pubitemid 40260888)
54. Iwamoto T, Pusztai L. Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data? Genome Med. 2010;2:81.
55. Weigelt B, Reis-Filho JS. Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Res. 2010;12(suppl 4):S5.
56. Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2- negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011; 17:6012-6020.
57. Mook S, Schmidt MK, Viale G, et al. The 70-gene prognosissignature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat. 2009;116:295-302.
58. Mook S, Schmidt MK, Weigelt B, et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol. 2010; 21:717-722.
59. Wittner BS, Sgroi DC, Ryan PD, et al. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res. 2008;14:2988-2993.
60. Knauer M, Mook S, Rutgers EJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010;120:655-661.
61. Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010;7:340-347.
62. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006;98:262-272. (Pubitemid 43264710)
63. Ivshina AV, George J, Senko O, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res. 2006;66:10292-10301. (Pubitemid 44799747)
64. Toussaint J, Sieuwerts AM, Haibe-Kains B, et al. Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics. 2009;10:424.
65. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817-2826. (Pubitemid 40051905)
66. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor- positive breast cancer. J Clin Oncol. 2006;24:3726-3734. (Pubitemid 46622311)
67. Habel LA, Shak S, Jacobs MK, et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res. 2006;8:R25.
68. Goldstein LJ, Gray R, Badve S, et al. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008;26:4063-4071.
69. Dowsett M, Cuzick J, Wale C, et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in nodenegative and node-positive postmenopausal patients withbreast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol. 2010;28:1829-1834.
70. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23:7265-7277. (Pubitemid 46202341)
71. Albain KS, Barlow WE, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor- positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11: 55-65.
72. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101:1446-1452.
73. Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287-5312. (Pubitemid 350232263)
74. Weigelt B, Horlings HM, Kreike B, et al. Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol. 2008;216:141-150.
75. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006; 98:1183-1192. (Pubitemid 44390989)
76. Desmedt C, Piette F, Loi S, et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res. 2007;13:3207-3214. (Pubitemid 46944903)
77. Cuzick J, Dowsett M, Pineda S, et al. Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health Recurrence Score in early breast cancer. J Clin Oncol. 2011; 29:4273-4278.
78. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007; 99:167-170.
79. Dowsett M, Nielsen TO, A'Hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103:1656-1664.
80. Bergamaschi A, Tagliabue E, Sorlie T, et al. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. J Pathol. 2008;214:357-367. (Pubitemid 351212391)
81. Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008; 14:518-527. (Pubitemid 351655218)
82. Teschendorff AE, Caldas C. A robust classifier of high predictive value to identify good prognosis patients in ERnegative breast cancer. Breast Cancer Res. 2008;10:R73.
83. Yau C, Esserman L, Moore DH, et al. A multigene predictor of metastatic outcome in early stage hormone receptornegative and triple-negative breast cancer. Breast Cancer Res. 2010;12:R85.
84. Oh E, Choi YL, Park T, et al. A prognostic model for lymph node-negative breast cancer patients based on the integration of proliferation and immunity. Breast Cancer Res Treat. 2011. Jun 11. DOI: 10.1007/s10549-011-1626-8 [Epub ahead of print].
85. Bianchini G, Qi Y, Alvarez RH, et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol. 2010;28:4316-4323.
86. Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29:1949-1955.
87. Ono M, Tsuda H, Shimizu C, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2011. May 12. DOI: 10.1007/s10549-011-1554-7 [Epub ahead of print].
88. Liedtke C, Hatzis C, Symmans WF, et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol. 2009;27:3185-3191.
89. Symmans WF, Hatzis C, Sotiriou C, et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol. 2010;28:4111-4119.
90. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res. 2009;15:2711-2722.
91. Natrajan R, Weigelt B, Mackay A, et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat. 2010;121:575-589.
92. Andre F, Job B, Dessen P, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009;15:441-451.
93. Chin SF, Teschendorff AE, Marioni JC, et al. Highresolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol. 2007;8:R215.
94. Chin K, DeVries S, Fridlyand J, et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006;10:529-541. (Pubitemid 44854748)
95. Jonsson G, Staaf J, Vallon-Christersson J, et al. Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res. 2010;12:R42.
96. Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol. 2011;223:307-317.
97. Flagiello D, Gerbault-Seureau M, Sastre-Garau X, et al. Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer. 1998;23:300-306. (Pubitemid 28507369)
98. Tsuda H, Takarabe T, Fukutomi T, et al. der(16)t(1;16)/ der(1;16) in breast cancer detected by fluorescence in situ hybridization is an indicator of better patient prognosis. Genes Chromosomes Cancer. 1999;24:72-77. (Pubitemid 28544465)
99. Smeets SJ, Harjes U, van Wieringen WN, et al. To DNA or not to DNA? That is the question, when it comes to molecular subtyping for the clinic! Clin Cancer Res. 2011; 17:4959-4964.
100. Bergamaschi A, Kim YH, Wang P, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer. 2006;45: 1033-1040. (Pubitemid 44435537)
101. Gravier E, Pierron G, Vincent-Salomon A, et al. A prognostic DNA signature for T1T2 node-negative breast cancer patients. Genes Chromosomes Cancer. 2010;49:1125-1134.
102. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084-6091.
103. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2: 489-501. (Pubitemid 37328931)
104. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29:4452-4461.
105. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist. 2011;16(suppl 1): 12-19.
106. Campbell IG, Russell SE, Choong DY, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678-7681. (Pubitemid 39446895)
107. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304:554. (Pubitemid 38541907)
108. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004;3:772-775. (Pubitemid 41351083)
109. Liedtke C, Cardone L, Tordai A, et al. PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res. 2008;10:R27.
110. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005;65:2554-2559. (Pubitemid 40490050)
111. Perez-Tenorio G, Alkhori L, Olsson B, et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res. 2007;13:3577-3584. (Pubitemid 46955118)
112. Hollestelle A, Elstrodt F, Nagel JH, et al. Phosphatidylinositol- 3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res. 2007;5:195-201. (Pubitemid 46424000)
113. Ellis MJ, Lin L, Crowder R, et al. Phosphatidyl-inositol-3- kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2010;119:379-390.
114. Weigelt B,Warne PH. Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene. 2011;30:3222-3233.
115. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancerspecific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA. 2007;104:5569-5574. (Pubitemid 47175721)
116. Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res. 2009;15:5049-5059.
117. Whyte DB, Holbeck SL. Correlation of PIK3Ca mutations with gene expression and drug sensitivity in NCI-60 cell lines. Biochem Biophys Res Commun. 2006;340:469-475. (Pubitemid 43021772)
118. Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA. 2007;104:7564-7569. (Pubitemid 47185946)
119. Panigrahi AR, Pinder SE, Chan SY, et al. The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol. 2004;204:93-100. (Pubitemid 39214486)
120. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999;155: 1253-1260. (Pubitemid 29488932)
121. Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol. 2001;14:672-676. (Pubitemid 32667211)
122. Marty B, Maire V, Gravier E, et al. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res. 2008;10:R101.
123. Shoman N, Klassen S, McFadden A, et al. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol. 2005;18:250-259. (Pubitemid 40188633)
124. Osborne CK, Shou J, Massarweh S, et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005;11:865s-870ss.
125. Loi S, Sotiriou C, Haibe-Kains B, et al. Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer. BMC Med Genomics. 2009;2:37.
126. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, et al. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther. 2011;10:1093-1101.
127. Drury SC, Detre S, Leary A, et al. Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. Endocr Relat Cancer. 2011; 18:565-577.
128. Vasudevan KM. Barbie DA, Davies MA, et al. AKTindependent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009;16:21-32.
129. Brachmann S, Fritsch C, Maira SM, et al. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol. 2009;21:194-198.
130. Tanaka H, Yoshida M, Tanimura H, et al. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res. 2011; 17:3272-3281.
131. Shuttleworth SJ, Silva FA, Cecil AR, et al. Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Curr Med Chem. 2011;18:2686-2714.
132. Andre F, Campone M, O'Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010;28:5110-5115.
133. Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer. 2008; 44:84-91. (Pubitemid 350256937)
134. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005;23:5314-5322. (Pubitemid 46206985)
135. Jerusalem G, Fasolo A, Dieras V, et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 2011;125:447-455.
136. Morrow PK, Wulf GM, Ensor J, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011;29:3126-3132.
137. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27:2630-2637.
138. Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol. 2009;27:4536-4541.
139. Aparicio SA, Huntsman DG. Does massively parallel DNA resequencing signify the end of histopathology as we know it? J Pathol. 2010;220:307-315.